Millipore Unveils Human Cancer Biomarker Panel

Millipore Corporation, a Life Science leader providing technologies, tools and services for the bioscience research and biopharmaceutical manufacturing industry, today announced the availability of the Beadlyte^® Human Cancer Biomarker Panel. The panel includes a Five-plex containing the biomarkers: Macrophage, Migration Inhibitory Factor (MIF), Prolactin, CA-125, Leptin and Osteopontin (OPN); and a Single Plex IGF-II assay. Each of the biomarkers has been identified in various tumor types including lung, breast, prostate and colorectal.

Dr. Gil Mor of Yale University used the Panel in research to detect all Stages of ovarian cancer. The profile of the six biomarkers isolated from serum was used with a unique algorithm developed by Dr. Mor’s laboratory to discriminate accurately between ovarian cancer patients and healthy subjects. The six biomarkers in the Panel demonstrate the significance of assessing biomarkers that change from the body’s response to the presence of cancer cells. Consequently, this panel will be a valuable tool for researchers studying the biochemical mechanisms and signals of all cancer stages.

The assays can be used to quantify these biomarkers in serum, plasma and cell/tissue culture supernatant samples. Each Panel includes all components to run the assay, standards and quality controls for each plex and can be easily adapted for high throughput automation. The Panel is highly sensitive, offering excellent intra- (<11%) and inter-assay (<10%) precision.

The integrated Millipore offers you more innovative technologies and stronger application support to streamline your progress and give you more confidence in your results. We’re deeply committed to having an in-depth understanding of key target classes for selectivity testing, including functional kinase, GPCR, and ion channel profiling assays, as well as extensively validated RIAs, ELISAs, and multiplex assays and bio-analytical service support for research or clinical studies.